tradingkey.logo
tradingkey.logo

Cibus Inc

CBUS
1.855USD
-0.275-12.91%
Market hours ETQuotes delayed by 15 min
952.01KMarket Cap
LossP/E TTM

Cibus Inc

1.855
-0.275-12.91%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Cibus Inc

Currency: USD Updated: 2026-03-27

Key Insights

Cibus Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 129 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.67.In the medium term, the stock price is expected to trend up.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cibus Inc's Score

Industry at a Glance

Industry Ranking
129 / 208
Overall Ranking
303 / 4542
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Cibus Inc Highlights

StrengthsRisks
Cibus, Inc. is an agricultural technology company that uses gene-editing technologies to develop plant traits in seeds. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits. It has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 100.28% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.64M.
Fairly Valued
The company’s latest PE is -0.68, at a medium 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 69.40K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.12.

Analyst Rating

Based on 3 analysts
Buy
Current Rating
14.667
Target Price
+588.58%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Cibus Inc is 4.96, ranking 206 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.06M, representing a year-over-year decrease of 12.79%, while its net profit experienced a year-over-year decrease of 35.43%.

Score

Industry at a Glance

Previous score
4.96
Change
0

Financials

4.37

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

6.91

Operational Efficiency

2.84

Growth Potential

3.61

Shareholder Returns

7.08

Cibus Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Cibus Inc is 8.68, ranking 13 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.68, which is -88.36% below the recent high of -0.08 and -235.37% above the recent low of -2.27.

Score

Industry at a Glance

Previous score
8.68
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 129/208
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Cibus Inc is 7.33, ranking 134 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 15.50, with a high of 25.00 and a low of 1.60.

Score

Industry at a Glance

Previous score
7.33
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts
Buy
Current Rating
14.667
Target Price
+588.58%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

92
Total
4
Median
7
Average
Company name
Ratings
Analysts
Cibus Inc
CBUS
3
Boston Scientific Corp
BSX
36
Intuitive Surgical Inc
ISRG
36
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
29
1
2
3
...
19

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Cibus Inc is 5.83, ranking 173 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 3.50 and the support level at 0.96, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
5.69
Change
0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.412
Neutral
RSI(14)
33.748
Neutral
STOCH(KDJ)(9,3,3)
12.784
Oversold
ATR(14)
0.419
Low Volatility
CCI(14)
-129.997
Sell
Williams %R
90.947
Oversold
TRIX(12,20)
-0.434
Sell
StochRSI(14)
0.000
Sell
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
2.472
Sell
MA10
2.751
Sell
MA20
3.193
Sell
MA50
2.697
Sell
MA100
2.137
Sell
MA200
1.806
Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Cibus Inc is 3.00, ranking 135 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 29.24%, representing a quarter-over-quarter decrease of 0.41%. The largest institutional shareholder is The Vanguard, holding a total of 1.24M shares, representing 1.79% of shares outstanding, with 34.43% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Riggs (Rory B)
14.63M
+396.82%
Fidelity Management & Research Company LLC
7.34M
+2.43%
JPL Investments SA
1.67M
-0.73%
The Vanguard Group, Inc.
Star Investors
962.37K
+12.41%
Vantage Consulting Group, Inc.
1.14M
--
Beetham (Peter Ronald)
382.44K
--
Gocal (Gregory Francis William)
374.84K
+19.06%
BlackRock Institutional Trust Company, N.A.
282.15K
-38.15%
Geode Capital Management, L.L.C.
262.71K
+1.93%
1
2

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cibus Inc is 1.90, ranking 171 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.89. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
1.90
Change
0
Beta vs S&P 500 index
1.98
VaR
+9.91%
240-Day Maximum Drawdown
+65.17%
240-Day Volatility
+112.92%

Return

Best Daily Return
60 days
+41.74%
120 days
+41.74%
5 years
+90.25%
Worst Daily Return
60 days
-25.78%
120 days
-25.78%
5 years
-34.32%
Sharpe Ratio
60 days
+1.14
120 days
+1.00
5 years
-0.29

Risk Assessment

Maximum Drawdown
240 days
+65.17%
3 years
+96.32%
5 years
+99.54%
Return-to-Drawdown Ratio
240 days
+0.06
3 years
-0.30
5 years
-0.20
Skewness
240 days
+0.24
3 years
+0.26
5 years
+1.80

Volatility

Realised Volatility
240 days
+112.92%
5 years
+129.67%
Standardised True Range
240 days
+10.36%
5 years
+148.19%
Downside Risk-Adjusted Return
120 days
+164.96%
240 days
+164.96%
Maximum Daily Upside Volatility
60 days
+125.04%
Maximum Daily Downside Volatility
60 days
+100.81%

Liquidity

Average Turnover Rate
60 days
+1.37%
120 days
+0.95%
5 years
--
Turnover Deviation
20 days
-11.75%
60 days
+103.34%
120 days
+41.79%

Peer Comparison

Healthcare Equipment & Supplies
Cibus Inc
Cibus Inc
CBUS
5.66 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc
TMO
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
Bioventus Inc
BVS
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
Anika Therapeutics Inc
ANIK
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI